The DESCAR-T registry was set up at the request of the health authorities to improve our knowledge of CAR T-cell therapies marketed in France to treat patients diagnosed with hematological malignancies. The objective of this registry is to collect data on the efficacy as well as on short- and long-term tolerance of these therapies in real-life setting.
The registry data really enables the realization of projects to answer specific research questions. One of these projects focuses on relapsed or refractory Primary Mediastinal B-cell Lymphoma (PMBL) after CART-cell therapy.
Why is this project being implemented?
Numerous retrospective studies have shown the interest of radiotherapy in reducing toxicity compared to standard treatments. However, there is no ongoing study on the French cohort concerning radiotherapy in peri -CAR-T cells management.
What are the objectives of this project?
This project aims to describe the dosimetric data of patients who have received a peri-infusion radiotherapy of CAR-T cells and to determine the profile of toxicities, efficacy and post-CART relapse profile according to the dose/volume/location of the radiotherapy.
How will the project be carried out?
The clinical data of patients on the registry who received pre-injection and post-injection radiotherapy are transferred by LYSARC to the Léon Bérard Center to assess the toxicity profile.
Radiotherapy reports and DICOM files from participating centres will be collected and analyzed centrally at the Centre Léon in order to correlate dose-volume parameters with toxicity, relapse profiles and response to CAR-T treatment.
FOR PATIENTS HAVING RECEIVED CAR-T IN FRANCE
What does this project involve for you?
This project concerns patients included in the DESCAR-T registry, patients diagnosed with primitive mediastinal cell B lymphoma (PMBL), relapsing after receiving treatment for CAR-T in France.
If you are in this situation and you accept that your data will be used for this project, this has no direct implication for you.
What should you do about this project?
There are two options:
- You do not object to the use of your data for this project:
⇒ in this case, you do not have to do anything
- You wish to object to the use of your data in this project:
⇒ in this case, please inform the doctor at the center where you have received your CAR T- treatement. You can also notify your decision by email at : dpo@lysarc.org.
You can find more information about your rights to object to the use of your data on the page “I am participating or have participated in a clinical trial